

RealRate

PHARMACEUTICAL 2022











RealRate

PHARMACEUTICAL 2022

Lipocine Inc. Rank 61 of 466



The relative strengths and weaknesses of Lipocine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipocine Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Lipocine Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 184% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	46,380
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,617
Liabilities, Non-Current	0
Other Assets	6,096
Other Compr. Net Income	-18
Other Expenses	0.20
Other Liabilities	1,296
Other Net Income	-3,780
Other Revenues	16,141
Property and Equipment	7.2
Research and Development	7,666
Selling, General and Administrative Expense	5,330

Output Variable	Value in 1000 USD
Assets	52,482
Liabilities	6,912
Expenses	12,996
Revenues	16,141
Stockholders Equity	45,570
Net Income	-634
Comprehensive Net Income	-643
Economic Capital Ratio	262%

